Show All Hide All

David Sabatini

Dr. David Sabatini is a Member of the Whitehead Institute for Biomedical Research, and he is Senior Associate Member at the Broad Institute, Member of the Koch Institute for Integrative Cancer Research, and a Professor of Biology, all with the Massachusetts Institute of Technology (MIT). He is also a Howard Hughes Medical Institute Investigator. David and his lab at the Whitehead Institute study the basic mechanisms that regulate growth, the processes whereby cells and organisms accumulate mass and increase in size, as well as the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis.

William C. Hahn

Dr. William C. Hahn is a medical oncologist and Professor in the Department of Medical Oncology at the Dana-Farber Cancer Institute. Also at Dana-Faber, he co-directs the Center for Cancer Genome Discovery and serves as the Chief of the Division of Molecular and Cellular Oncology as well as Chair of the Executive Committee for Research. He is an Institute Member of the Broad Institute of MIT and Harvard. Dr. Hahn has made numerous seminal discoveries that have informed our current molecular understanding of cancer and which have defined new conceptual paradigms and formed the foundation of new translational studies.

Aviv Regev

Dr. Aviv Regev, a computational and systems biologist, is a Professor of Biology at MIT, a Howard Hughes Medical Institute Investigator, as well as Chair of the Faculty and Director of the Klarman Cell Observatory and Cell Circuits Program at the Broad Institute. Dr. Regev's research centers on understanding how complex molecular circuits function and evolve in the face of genetic and environmental changes over timeframes ranging from minutes to millions of years. She has pioneered many leading methods for the reconstruction of circuits in mammalian cells, including in single-cell genomics.

Arnold Levine

Dr. Arnold Levine is Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton, New Jersey. He is best known for his 1979 discovery of the tumor suppressor gene p53, a molecule that inhibits tumor development. His research has fueled the design of a new generation of anti-cancer therapies that utilize inhibition of protein-protein interactions in cancer cells to initiate cell death.

Tyler Jacks

Dr. Tyler Jacks is the Director of MIT’s Koch Institute for Integrative Cancer Research and the David H. Koch Professor of Biology at MIT. He has pioneered the use of gene-targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, brain and ovary. His lab has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment.

Edison T. Liu

Dr. Edison T. Liu joined The Jackson Laboratory in 2012 as President and CEO and is the director for The Jackson Laboratory Cancer Center. Previously, he served for 10 years as the founding Executive Director of the Genome Institute of Singapore and as the President of the international Human Genome Organization (HUGO). Dr. Liu’s research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes and deciphering the dynamics of gene regulation on a genomic scale. He has authored more than 300 scientific papers and reviews and co-authored two books.

Steve Gygi

Dr. Steve Gygi received his Ph.D. from the University of Utah in the area of pharmacology and toxicology. He joined the faculty at Harvard Medical School in 2000. He is currently a Professor in the Department of Cell Biology. Dr. Gygi is a technologist who uses mass spectrometry to answer fundamental questions in both normal and abnormal biology. He specializes in instrumentation advances for global cellular protein measurements.

C. Martin Harris , MD

Dr. Harris has been a director of the Company since March 2012. He is currently Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at the University of Texas at Austin. Previously, he was CIO and Chairman of the Information Technology Division, as well as a Staff Physician at The Cleveland Clinic Foundation Department of General Internal Medicine. He also served as a Staff Physician for the Cleveland Clinic Hospital. He is currently a director of Invacare Corporation, HealthStream, Inc. and Colgate-Palmolive Company.

Thermo Fisher Scientific At a Glance

NYSE: TMO (Common Stock)Apr 24, 2017 04:02 PM

Exchange NYSE (US Dollar)NYSE

Price 157.34

Change +2.30  (+1.48%)

Volume 1,198,329

% Change

Intraday High 157.64

52 Week High 161.66

Intraday Low 156.03

52 Week Low 139.07

Today's Open 156.53

Previous Close 155.04

Minimum 20 minute delay

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

The world leader in serving science